

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer ID1443

#### Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Bayer (darolutamide)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Black Health Agency</li> <li>• Bob Champion Cancer Trust</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• HAWC – Help Adolescents with Cancer</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Macmillan Cancer Support</li> <li>• Maggie’s Centres</li> <li>• Marie Curie</li> <li>• Muslim Council of Britain</li> <li>• Orchid</li> <li>• Pelican Cancer Foundation</li> <li>• PCaSO - Prostate Cancer Support Organisation</li> <li>• Prostate Cancer UK</li> <li>• Prostate Help Association</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Tackle Prostate Cancer</li> <li>• Tenovus Cancer Care</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Anaesthetists</li> <li>• Association of Cancer Physicians</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association of Urological</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord (bicalutamide)</li> <li>• AstraZeneca UK (bicalutamide, goserelin)</li> <li>• Bayer (cyproterone acetate)</li> <li>• Concordia International (leuprorelin)</li> <li>• Ferring Pharmaceuticals (degarelix, triptorelin)</li> <li>• Generics UK T/A Mylan (flutamide)</li> <li>• Ipsen (triptorelin)</li> <li>• Orion Pharma UK (histrelin)</li> <li>• Sanofi (buserelin)</li> </ul>

Final stakeholder list for the technology appraisal of darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer ID1443

Issue date: January 2020

© National Institute for Health and Care Excellence 2020. All rights reserved

Consultees	Commentators (no right to submit or appeal)
<p>Nurses</p> <ul style="list-style-type: none"> <li>• British Association of Urological Surgeons</li> <li>• British Geriatrics Society</li> <li>• British Institute of Radiology</li> <li>• British Prostate Group</li> <li>• British Psychosocial Oncology Society</li> <li>• British Uro-Oncology Group</li> <li>• Cancer Research UK</li> <li>• Prostate Cancer Advisory group</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Radiologists</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Health Forum</li> <li>• UK Oncology Nursing Society</li> <li>• Urology Foundation</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS South Reading CCG</li> <li>• NHS Swindon CCG</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Sunpharma (bicalutamide)</li> <li>• Takeda UK (leuprorelin)</li> <li>• Wockhardt UK (cyproterone acetate)</li> <li>• Zentiva (bicalutamide)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Cochrane Urology</li> <li>• Everyman</li> <li>• Genomics England</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Ovarian &amp; Prostate Cancer Research Trust</li> <li>• Pro Cancer Research Fund</li> <li>• Prostate Cancer Research Centre</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

Final stakeholder list for the technology appraisal of darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer ID1443

Issue date: January 2020

© National Institute for Health and Care Excellence 2020. All rights reserved

## **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.